A subsidiary of Hangzhou, China-based Ascletis Pharma Inc. has negotiated an exclusive license from Suzhou, China-based Suzhou Alphamab Co. Ltd. to develop and commercialize the anti-PD-L1 candidate KN-035 to treat hepatitis B and other viral diseases in greater China. Ascletis will make both an up-front payment and potential milestone payments to Alphamab as well as tiered royalties from the midteens to around 20 percent on any future sales.